| Texto completo | |
| Autor(es): Mostrar menos - |
Xavier, Gabriela
;
Ota, Vanessa
;
Kajitani, Gustavo Satoru
;
Mauer, Jessica H.
;
Asprino, Paula Fontes
;
Costa, Giovany Oliveira
;
Cavalcante, Daniel A.
;
Cerqueira, Raphael
;
Novaes, Antonio
;
Santos, Felipe R. Dos
;
Gadelha, Ary
;
Noto, Cristiano
;
Boim, Mirian A.
;
Galante, Pedro A. F.
;
Santoro, Marcos Leite
;
Belangero, Sintia Iole
Número total de Autores: 16
|
| Tipo de documento: | Artigo Científico |
| Fonte: | SCHIZOPHRENIA RESEARCH; v. 286, p. 8-pg., 2025-10-21. |
| Resumo | |
First-episode psychosis (FEP) represents a critical period characterized by severe psychotic symptoms, where early intervention is vital. Identifying objective biomarkers to assess symptoms and guide treatment remains a significant challenge. Extracellular vesicles (EVs), particularly their microRNAs (miRNAs), emerge as promising candidates due to their ability to cross the blood-brain barrier and modulate gene expression. Since antipsychotic medications can influence miRNA expression, studying antipsychotic-na & iuml;ve FEP patients is crucial for isolating disease-specific changes. This study analyzed miRNA expression in serum EVs from 12 antipsychotic-na & iuml;ve FEP patients, before and after two months of risperidone treatment, comparing results to 12 healthy controls. Nextgeneration sequencing (NGS) identified 613 miRNAs in total; after filtering out low-expressed transcripts, 428 miRNAs were retained for differential expression analysis. Two miRNAs-miR-335-5p and miR-30d-5p presented reduced expression in FEP patients compared to controls. This reduction persisted after treatment but showed signs of attenuation. Notably, miR-30d-5p expression was negatively correlated with depressive symptoms assessed via the Calgary Depression Scale for Schizophrenia. Additionally, miR-744-5p was upregulated following risperidone treatment, suggesting a potential modulatory effect of the drug on EV miRNA expression. Both miR-30d-5p and miR-744-5p have been previously implicated in mental disorders, neurodevelopment, and schizophrenia-related pathways, with confirmed expression in neurons. Here we also observed that predicted targets from these miRNAs are involved in synaptic related pathways. Although limited by the small sample size, our findings propose novel avenues for psychosis research and biomarker discovery. (AU) | |
| Processo FAPESP: | 16/19462-2 - O papel dos miRNAs na esquizofrenia: do genoma à proteína |
| Beneficiário: | Gabriela Xavier |
| Modalidade de apoio: | Bolsas no Brasil - Doutorado Direto |
| Processo FAPESP: | 10/08968-6 - Investigação de marcadores genéticos e epigenéticos: uma abordagem translacional para o tratamento de esquizofrenia |
| Beneficiário: | Síntia Iole Nogueira Belangero |
| Modalidade de apoio: | Auxílio à Pesquisa - Regular |
| Processo FAPESP: | 17/18246-7 - Genes colocalizados: estudo de mútua regulação de biogênese entre genes codificadores e não codificadores |
| Beneficiário: | Felipe Rodolfo Camargo dos Santos |
| Modalidade de apoio: | Bolsas no Brasil - Doutorado Direto |
| Processo FAPESP: | 14/07280-1 - Busca por marcadores genéticos de risco, de progressão e de reposta ao tratamento na esquizofrenia |
| Beneficiário: | Síntia Iole Nogueira Belangero |
| Modalidade de apoio: | Auxílio à Pesquisa - Regular |
| Processo FAPESP: | 23/05560-6 - Abordagens genéticas e epigenéticas como modelos preditivos em transtornos mentais |
| Beneficiário: | Marcos Leite Santoro |
| Modalidade de apoio: | Auxílio à Pesquisa - Jovens Pesquisadores |
| Processo FAPESP: | 17/25016-8 - Investigação da resposta ao tratamento da esquizofrenia com risperidona: estudo farmacogenético em uma coorte de pacientes em primeiro episódio psicótico |
| Beneficiário: | Síntia Iole Nogueira Belangero |
| Modalidade de apoio: | Auxílio à Pesquisa - Regular |